Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That stock was at 4 dollars recently lost 75 percent not great feeling
“We are progressing with our Phase 1 trials with gp96 (HS-110) in combination with local OX40L (HS-130) and checkpoint inhibition as well as our gp96-based COVID-19 vaccine, and look forward to providing further clinical updates."
NEWS -- Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator
New patent covers ICOS T cell co-stimulation in combination with Heat's proprietary gp96 platform
DURHAM, NC / ACCESSWIRE / October 7, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced it has been issued a new US patent (US Patent No. 10,780,161) covering compositions of matter that are part of Heat's gp96 platform (antigen presentation, T cell activation, TLR activation) in combination with Inducible T cell Co-stimulator (ICOS) ligand or ICOSL, a T cell immune booster, in a single therapy. The goal of the combination therapy is to boost immunity to potentially overcome the immunosuppressive tumor microenvironment and address the needs of patients refractory to current therapies.
This newly issued US patent complements Heat's growing patent estate around its platform technology, which also includes a U.S. patent covering Heat's gp96 platform in combination with OX40L, a T cell costimulatory agonist. Pre-clinical studies combining Heat's secreted gp96 plus OX40L T cell co-stimulator in a single therapy, administered locally, have demonstrated superior activity compared to gp96 in combination with conventional OX40 antibody administered systemically by IV infusion.
Heat's gp96 combination with a T cell co-stimulator is expected to have utility in combating viral infections, beyond its potential in oncology. The presentation of immunogenic viral antigens via gp96 (for example the S-protein in COVID-19 infection) and induction of innate immunity along with potent activation/boost of cellular immunity via killer CD8+ T cells is expected to be instrumental in eradicating both SARS-CoV-2 infected cells or tumor cells. In pre-clinical studies, Heat's gp96 based COVID-19 vaccine has demonstrated the ability to generate lung tissue-resident memory CD8+ T cells which are vital in destroying SARS-CoV-2 infected cells. This novel COVID-19 vaccine approach may be particularly important in treating immunocompromised patient populations.
Jeff Wolf, Chief Executive Officer of Heat, commented, "This new patent strengthens our gp96 intellectual property portfolio by adding another T cell costimulatory agonist to our arsenal. We believe our novel single therapy combination approach that initiates local and specific T cell activation provides competitive advantages over conventional antibody therapies by limiting systemic toxicity and lowering the significant cost required when combining multiple biological therapies. We are progressing with our Phase 1 trials with gp96 (HS-110) in combination with local OX40L (HS-130) and checkpoint inhibition as well as our gp96-based COVID-19 vaccine, and look forward to providing further clinical updates."
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial. For more information, please visit: http://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as Heat's gp96 combination with T cell co-stimulator platform having utility in combating viral infections beyond its promise in oncology, the presentation of immunogenic viral antigens via gp96 and induction of innate immunity along with potent activation/boost of cellular immunity via killer CD8+ T cells being instrumental in eradicating both SARS-CoV-2 infected cells or tumor cells, Heat's COVID-19 vaccine approach being particularly important in treating compromised patient populations, Heat's combination single therapy approach that initiates local and specific T cell activation providing competitive advantages over conventional antibody therapies in limiting systemic toxicity and lowering the significant cost attributed to combining multiple biological therapies, Heat's innovative gp96 platform with T cell immune boosters holding significant potential, especially in treating the vast majority of checkpoint inhibitor refractory patients, progressing with Heat's Phase 1 trials with gp96 (HS-110) in combination with OX40L (HS-130) and checkpoint inhibition and providing further clinical updates. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability to use Heat's gp96 combination with T cell co-stimulator platform to combat viral infections, including COVID-19, the ability of immunogenic viral antigens via gp96 and induction of innate immunity along with potent activation/boost of cellular immunity via killer CD8+ T cells to eradicate both SARS-CoV-2 infected cells or tumor cells, the ability to use Heat's COVID-19 vaccine approach to treat compromised patient populations, the ability of Heat's combination single therapy approach to provide competitive advantages over conventional antibody therapies in limiting systemic toxicity and lowering the significant cost attributed to combining multiple biological therapies, the ability of Heat's gp96 platform with T cell immune boosters to treat checkpoint inhibitor refractory patients, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
SOURCE: Heat Biologics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/609447/Heat-Biologics-Issued-Additional-Patent-on-gp96-Combination-Platform-Therapy-with-T-cell-Co-Stimulator
Side effects of current vaccine candidates noted:
https://finance.yahoo.com/m/c68c9c6a-5c5a-351f-9c44-b3f51bcfff43/report-moderna-and-pfizer.html
Dr. James Todaro will discuss T-Cell immunity tonight on Laura Ingraham's show on Fox. He's worth a follow on Twitter if this subject interests you.
HTBX should do very well in the CV battle.
Dr. Atlas explains T-cell immunity on @IngrahamAngle tonight stating evidence suggests T-cell immunity:
— James Todaro, MD (@JamesTodaroMD) September 25, 2020
- comes from prior coronaviruses
- is the reason children are less affected by COVID-19
- is more important than antibodies
- is why fewer people are susceptible to COVID-19 pic.twitter.com/BmitGEwtcs
So if you missed it Dr. Scott Atlas just confirmed today in President Trumps news conference what I have been saying and that the T-cell immunity is more important based on the science and proven studies than antibodies when it comes to immunity. Then after that Larry Kudlow came on with good news on the economy which I hope helps lift markets tomorrow. Watch
$HTBX President Trump talked about Monoclonal technology for Covid 19 today in this press conference, 1 minute 25 seconds into it , Pelican which is Heats subsidiary is working on Monoclonal therapies
HTBX stock will go back up soon. NO worries. Be happy !
Buy cheap shares now before it is going back up quick!
HTBX stock will go back up soon. NO worries. Be happy !
Buy cheap shares now!
Stopped out to protect profit, damn. dont think this is done. Will keep an eye on it to enter again.
We dont need any stinky PRs. HTBX is the stock to own. Buy now at cheap price before the PPS goes up high!
Still no PR on the new patent?
Heard they now working on mosquito repellent
Go Htbx
* * $HTBX Video Chart 09-18-2020 * *
Link to Video - click here to watch the technical chart video
Lots of extra action on many stocks today due to Options Expiration. This is a unique date. So the stock may have been held back for some to make money. Monday will be interesting. I am long. GL!
People are selling on the news and the same good news are out.
Clay Trader is at work again?
* * $HTBX Video Chart 09-17-2020 * *
Link to Video - click here to watch the technical chart video
HTBX: Breaking into the Big Leagues: $100 Million + 3 Clinical Candidates
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/HTBX-Breaking-into-the-Big-Leagues-100-Million--3-Clinical-Candidates-article/default.aspx
HTBX will continue to go up after all the flippers are done selling
It would be nice to see $2 or more sometimes tomorrow
Can’t believe you are still touting your wares
Just In: $HTBX 4 Penny Stocks On Robinhood Reaching New September Highs
Are New Highs Coming For These Penny Stocks? This week, penny stocks are experiencing a big surge of interest. Whether or not it has something to do with the massive IPOs is a question for another time. The Snowflake IPO , for example, has become one of the biggest tech IPOs in history. Whi...
In case you are interested HTBX - 4 Penny Stocks On Robinhood Reaching New September Highs
* * $HTBX Video Chart 09-16-2020 * *
Link to Video - click here to watch the technical chart video
HTBX Price target in the immediate future is $3.50. We should be going incrementally up every day or every other day until we reach the target price. Any other positive news will push it there quickly.
Please see link,
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/HTBX-Breaking-into-the-Big-Leagues-100-Million--3-Clinical-Candidates-article/default.aspx
We have been told that T-cell vaccine is the best solution to go, but we are not at same stage of clinical trial as that of Astrazeneca to say more.
Huge stacks on the bid at 1.13 now moved to 1.14 - interesting
Just want from a science perspective to show how dangerous the antibody response in the other antibody response vaccines could be without proper safety testing. Del Bigtree testified and told the CDC how dangerous these vaccines could be to our entire human species. HTBX has a completely different and safer approach boosting T-cells. Here is the article he was referring to. https://www.sciencedirect.com/science/article/pii/S2589909020300186?via%3Dihub
Video here https://www.bitchute.com/video/7LZZ3eXk9dBt/
Every day we have an excuse. But the price always tell us the true...lol
$HTBX Jeff Wolf CEO talks 4 times in today's webinar 8:03 , 24:24 ,33:28, 47:14
I believe the conference went well where the CEO shined. Our T-cell vaccine rocks.
We are having the global stock market correction as we speak. Look at other stocks. Most of them are down as well.
Cash is king at this time
Can anyone tell us how the conference went and what the CEO said?
HTBX Added under a $1.00 a few days ago.
T cell platforms are going to be valuable assets.
2 micro caps I like in the T Cell Space. Massive upside Nice engulfing hammers put in recently TA bump coming on both T cell plays.
HTBX 190 million market nice pipeline for cancer and CV-19 Vaccine
https://www.heatbio.com/product-pipeline
https://d1io3yog0oux5.cloudfront.net/_6797857acbf592c9d30ad232160e07d7/heatbio/db/466/5424/pdf/Heat+Biologics+Corporate+Presentation+%28August+2020%29.pdf
PDSB 48 Million dollar market cap T cell Cancer second generation CV-19 Flu & multiple infectious Disease vaccines. 22 million shares insiders & tutes own 45% 30 million cash low burn rate cash runway for 2 years
https://www.pdsbiotech.com/
https://www.pdsbiotech.com/pipeline/oncology
https://www.pdsbiotech.com/pipeline/infectious-disease
https://www.pdsbiotech.com/images/presentation/PDS_Biotech_Corporate_Presentation_SEPTEMBER2020.pdf
$PDSB 20,000 Long
$HTBX 44,000 Long
This is why I believe in the end the T-Cell immunity approach will win out with HTBX over any other type of RNA vaccine which has never been successful or safe. Watch this video then check out the article on Pathogenic Priming.
NEWS -- Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th
DURHAM, NC / ACCESSWIRE / September 9, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, will participate on a virtual panel, entitled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET.
The virtual panel discussion will also include: Tom Equels, CEO of AIM ImmunoTech Inc. (AIM); Dr. David Jin, President and CEO of Avalon GlobloCare Corp. (AVCO); Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd. (IPA) (IPATF) (TQB2) and Vered Caplan, CEO of Orgenesis Inc. (ORGS).
The event brings together executives from leading biopharmaceutical companies to discuss how their companies are helping address the COVID-19 pandemic. The panel will be moderated by broadcast journalist Christine Corrado of Proactive Investors. Investors interested in attending the event can register at: https://zoom.us/webinar/register/8215990551540/WN_YFe8n6dQSm6mpgG3iWfF-w.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.
For more information, please visit: http://www.heatbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
SOURCE: Heat Biologics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/605211/Heat-Biologics-CEO-to-Participate-in-Virtual-Panel-New-Approaches-to-COVID-19-Hidden-Breakthroughs-on-Thursday-September-10th
Wow didnt think my statement would be proven true that fast. https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/
CEO Wolf at conference https://news.yahoo.com/iiroc-trading-halt-gdbo-194100082.html
* * $HTBX Video Chart 09-08-2020 * *
Link to Video - click here to watch the technical chart video
HTBX vaccine will be the first vaccine to be successfully deployed to human kind
My opinion is this vaccine approach with T-cells is much different and safer than all the RNA vaccine candidates. FYI there has never been a successful RNA coronavirus vaccine in HISTORY.
HTBX presentation in UK
https://www.proactiveinvestors.co.uk/companies/news/928527/heat-biologics-meet-the-team-behind-a-robust-covid-19-vaccine-928527.html
HTBX PPS should be in the same level with INO PPS. Should be in the teens for God's sake and human kind
i`m happy and i`m out.......hope it keeps runnin ...gla
$$$$$$$$$$$$$ HTBX $$$$$$$$$$$$$
added 95`s on fri ...and 95`s early this morn.. been selling 117`s and some 118`s....almost empty.........120`s coming up , and i`ll be out....glta
$$$$$$$$$$$$$$$$$ HTBX $$$$$$$$$$$$$$
Followers
|
155
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6042
|
Created
|
01/26/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |